^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Cutaneous Melanoma
    Drug:Mektovi (binimetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/19/2021
    Excerpt:
    Melanoma: Cutaneous...Metastatic or unresectable disease…Useful in certain circumstances…Binimetinib for NRAS-mutated tumors that have progressed after prior immune checkpoint inhibitor therapy
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

    Excerpt:
    ...- BRAF or NRAS mutation in tumor tissue...
    Trial ID:
    NCT01320085
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

    Excerpt:
    ...- Presence of NRAS Q61 mutation in tumor tissue prior to randomization as determined by a Novartis designated central laboratory...
    Trial ID:
    NCT01763164